INVIVYD INC. - COMMON

Invivyd Announces Changes to Executive Team

03 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

06 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

17 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

10 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference

09 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights

02 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

24 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

13 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

12 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

12 Sep 2022 07:15:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces Corporate Name Change to Invivyd

12 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

06 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

15 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

05 Jul 2022 07:25:58 By Nasdaq GlobeNewswire

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors

01 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports First Quarter 2022 Financial Results

13 May 2022 06:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request

14 Apr 2022 07:45:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

30 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

18 Mar 2022 18:33:15 By Nasdaq GlobeNewswire